XXXX for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study.

@entity1 @entity2708 @entity1138 @entity1139 @entity86 @entity5862
OBJECTIVE: @entity1138 ( @entity1139 ) is an antineoplastic agent that has been shown to decrease scar tissue after ophthalmologic surgery. Our goal was to determine whether the application of @entity1139 at the conclusion of sinus surgery decreases the incidence of @entity86 formation. METHODS: At the completion of endoscopic sinus surgery in 55 @entity1 , a @entity2708 pledget saturated with 1 mL of 0.4 mg/mL @entity1139 was placed for 4 minutes in the right or left middle meatus and a similar saline-soaked pledget was placed on the opposite side. @entity1 were examined postoperatively by a masked observer for the presence of @entity5862 and mucosal changes. RESULTS: Postoperative adhesions were observed in 16 @entity1 (29%) with a mean follow-up of 4.1 months. These adhesions were bilateral in 6 @entity1 (10.9%) and unilateral in 10 @entity1 (18%). Unilateral adhesions were observed on only 2 sides (3.6%) treated with @entity1139 and 8 controls (14.5%) (P = 0.058). No adverse effects were observed. CONCLUSIONS: @entity1139 was found to be safe to use during sinus surgery, and it may reduce the incidence of postoperative adhesions at the dosage used in this study. SIGNIFICANCE: Because of the observed trend toward decreased @entity5862 formation with @entity1139 application, further trials using higher concentrations and application times are warranted.
